GLP-1 Users Reported Lifting Nails Four Times as Often as Nonusers: The Evidence on Hair and Nail Changes

Hair loss already appears in the U.S. prescribing information for Wegovy and Zepbound. Nails are newer territory. At the European Academy of Dermatology and Venereology (EADV) Congress in Vienna, held September 30 to October 3, 2026, researchers reported that people taking GLP-1 drugs described nail detachment about four times as often as similar people who had never taken them: 39% versus 9%. Doctors call this onycholysis. The nail lifts so that it is no longer fully attached to the skin underneath, which usually shows up as a white area.

"Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal," co-author Charles Taïeb said, according to HCPLive. The survey put numbers on complaints that had mostly circulated among patients, and it also found more hair shedding and scalp irritation (our October 3 digest covered it). Those numbers are much higher than the hair loss rates in the drugs' clinical trials, and the gap says a lot about how each kind of study counts side effects.

The work was presented as two companion abstracts, one on nails and one on hair and scalp, by a team that included Taïeb and dermatologist Bruno Halioua of the Institut Alfred Fournier in Paris. Both compared 575 adults taking a GLP-1 receptor agonist with 1,329 adults who had type 2 diabetes, obesity, or both and had never used one. Participants came from France, the United States, Brazil, and Mexico. Gizmodo reported that users had been on treatment for an average of 18.5 months. No dermatologist examined anyone, so every result reflects what people said about their own hair and nails.

Among users, 66% reported at least one nail problem, compared with 53% of nonusers, and 46% reported nail discoloration, compared with 17%. On the scalp, 50% of users described unusual hair loss and 42% described thinner hair, versus 34% and 19% of nonusers. About a quarter of users (26%) said their hair loss began after they started treatment, and scalp redness was about three times as common in users. After the researchers adjusted for differences between the groups, nail detachment and discoloration remained about two to three times as frequent among users.

Two details limit what this can prove. About half of the users said they had nail problems before they started a GLP-1. The studies were also cross-sectional, a single snapshot in time, which can reveal an association but cannot show that the drugs caused the changes. Neither study has been published in a peer-reviewed journal yet.

The FDA-approved labels for Wegovy (semaglutide) and Zepbound (tirzepatide) count hair loss in placebo-controlled trials. In three trials that treated 2,116 adults with Wegovy 2.4 mg for up to 68 weeks, 3.3% reported hair loss, compared with 1% on placebo. In trials of the newer Wegovy 7.2 mg dose, the rate rose to 5.8%. Zepbound was tested in two trials that treated 2,519 adults for up to 72 weeks, and hair loss was reported by 4% to 5% of people across the 5, 10, and 15 mg doses, versus 1% on placebo.

The labels share two patterns. Women reported hair loss far more often than men: 8.4% of women versus 0.2% of men on Wegovy 7.2 mg, and 7.1% of women versus 0.5% of men on Zepbound. Both labels also state that hair loss reports "were associated with weight reduction." Few people quit over it. In the Zepbound trials, nobody on the drug stopped because of hair loss, though one person on placebo did, and in the Wegovy 7.2 mg trials one hair loss event led to permanent discontinuation.

So why did half of the survey's users report unusual hair loss when trials found about 5%? The two designs ask different questions. Trials log side effects as they come up during the study, while the Vienna team asked people directly about hair and nails. The survey's own control group gives a better baseline: 34% of people who had never taken a GLP-1 also reported unusual hair loss, so hair complaints are common in this population with or without the drug. The labels also warn that side effect rates cannot be compared directly across different drugs' trials, so the Wegovy and Zepbound figures are not a ranking.

Dermatologists have a name for shedding that follows a shock to the body: telogen effluvium. The American Academy of Dermatology (AAD) says shedding 50 to 100 hairs a day is normal, and it lists losing 20 pounds or more among the stressors that can trigger excessive shedding, alongside giving birth or having surgery. Most people notice it a few months after the trigger. The AAD says hair tends to regain its normal fullness within six to nine months, though shedding can last longer if the stressor stays. The labels' finding that hair loss tracked weight reduction fits this pattern.

Eating less may add to it. A 2025 joint advisory from four U.S. medical and nutrition societies noted that people on GLP-1s cut calorie intake by 16% to 39%. It warned that intakes below about 1,200 calories a day for women or 1,800 for men can leave people short on vitamins and minerals, including iron, zinc, and vitamin B12, and it lists excessive hair loss among the signs of a nutrient deficiency.

The Vienna team argues that weight loss does not explain everything. HCPLive reported that the nail differences held up when the researchers looked only at people who had lost weight, and Gizmodo reported that scalp problems did not track the amount of weight lost. Hair loss in users usually came with itching, redness, or scaling. Halioua said that what is happening on the scalp "may go beyond the classical shedding seen after rapid weight loss and involve an inflammatory component." No one has tested that idea yet.

Earlier reviews could not settle the question. A 2025 scoping review in Cureus found nine studies and more than 1,000 spontaneous hair loss reports in the FDA's adverse event database, but most studies had no dermatologist confirm the diagnosis. Only one described the type of hair loss, mostly telogen effluvium and pattern hair loss. A separate 2025 systematic review of five studies covering 2,905 adults found conflicting results, with some studies reporting hair loss and others reporting improvement and regrowth.

No one has shown why GLP-1 users would report more nail detachment. According to the AAD, a lifting nail is often caused by a fungal infection or psoriasis. Injury can also do it, such as from a harsh manicure or from cleaning under the nails with a sharp object. A survey cannot tell those causes apart from a drug effect. And since half of users had nail trouble before treatment, the starting point was already high.

The researchers plan new studies that follow people from the day they start a GLP-1. Under that plan, dermatologists would examine the scalp and nails under magnification, and blood tests would check iron, zinc, vitamin B12, vitamin D, and protein status. That design could show whether nail changes appear after treatment begins and whether they line up with a deficiency.

Gizmodo reported that the project was funded by Pierre Fabre, which it described as one of the largest dermo-cosmetics firms in the world. Pierre Fabre's brands include Ducray, a hair and scalp care line, and René Furterer, and Gizmodo noted that the company has a commercial interest in this research. Funding from a company does not make the numbers wrong. It does mean the sponsor sells products for the problem the survey measured, which is worth knowing before buying anything marketed to GLP-1 users for hair or nails.

Supplement makers are running their own tests. Olistic Research Labs, a Spanish company, registered a randomized, placebo-controlled trial of its drinkable supplement for hair loss in people taking GLP-1/GIP receptor agonists, with a planned enrollment of 40. The six-month study began enrolling in Madrid in March 2026 and has not posted results.

Taïeb's message to patients, as quoted by Gizmodo, was: "do not panic, and do not stop an effective treatment on your own because of your hair or nails—but do mention these symptoms to your doctor." Halioua said the changes are frequent and usually benign, according to HCPLive. The trial data fit that calm reading, since hair loss rarely led anyone to stop treatment.

Steps that follow from the evidence:

• Note when the shedding started. Shedding that begins a few months after fast weight loss matches the telogen effluvium pattern the AAD describes, and dates or photos help your prescriber judge it.
• Check how much you are eating. The joint advisory notes that targets of 1.2 to 1.6 grams of protein per kilogram a day have been proposed during active weight loss, and it offers 80 to 120 grams a day as a simpler goal. Our guide to protein and resistance training on GLP-1s covers how to reach it with a smaller appetite.
• Ask whether blood tests make sense if your intake is very low. Iron, zinc, and vitamin B12 are on the advisory's list of nutrients of concern, and the Vienna team plans to measure the same ones.
• Have a lifting nail examined. The AAD says a dermatologist should look at any nail that is lifting, since you may need treatment to clear an infection. Redness and swelling around a nail can also signal infection.
• Mention an itchy, red, or scaly scalp. Halioua said scalp inflammation "was the rule rather than the exception" in the hair study and "may be treatable."

Ask to see trial results before paying for a hair supplement sold to GLP-1 users; the Olistic trial, for one, has none yet. If hair or nail changes bother you enough that you are thinking about stopping the drug, raise it with your prescriber, who can weigh it against what the medicine is doing for your weight and blood sugar.